Dyne Therapeutics Reports Q1 Results, Confirms DMD BLA Submission on Track for Q2 2026, Extends Cash Runway
DYN has more than doubled off its 52-week low of $8.06.
Summary
Dyne Therapeutics reported Q1 2026 financial results, including a net loss of $(120.9) million, while reaffirming its cash runway into Q1 2028 and providing positive updates on its lead clinical programs for DMD and DM1, including BLA submission timelines.
Key Events · Earnings and Guidance · DYN
-
Q1 2026 Financial Results
Reported a net loss of $(120.9) million, or $(0.73) per diluted share, for Q1 2026. R&D expenses decreased to $100.9 million, while G&A expenses increased to $24.4 million due to launch preparation.
-
Cash Runway Extended
Cash, cash equivalents, and marketable securities stood at $972.2 million as of March 31, 2026, sufficient to fund operations into Q1 2028.
-
DMD Program (z-rostudirsen) on Track for BLA Submission
Completed a positive pre-BLA meeting with the FDA and remains on track to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026, with a potential U.S. launch in Q1 2027. A global confirmatory Phase 3 trial will also initiate in Q2 2026.
-
DM1 Program (z-basivarsen) Advances
Reached the enrollment target of 60 participants in the ACHIEVE registrational expansion cohort, with data expected in Q1 2027 to support a potential BLA submission in early Q3 2027. The global confirmatory Phase 3 HARMONIA trial was initiated in March 2026.
Analysis · DYN · Life Sciences
This filing is highly important as it provides a comprehensive update on Dyne Therapeutics' financial health and, more critically, its clinical pipeline. The confirmation of a positive pre-BLA meeting and the timeline for BLA submission for its Duchenne muscular dystrophy (DMD) program (z-rostudirsen) in Q2 2026, with a potential launch in Q1 2027, represents a significant de-risking event and a major step towards commercialization. Simultaneously, the DM1 program (z-basivarsen) is also advancing well, with enrollment targets met and a Phase 3 trial initiated. The extended cash runway into Q1 2028 provides financial stability to execute on these critical milestones.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $17.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.